

[Dinoprostone \(prostaglandin E2\)](#)

Not recommended as an essential medicine

Section:

[22. Medicines for reproductive health and perinatal care](#) [22.7. Medicines administered to the neonate \[c\]](#)

ATC codes: [G02AD02](#)

EMLc

Indication

Other specified congenital anomaly of great arteries including arterial duct ICD11 code: [LA8C.Y](#)

INN

Dinoprostone

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 1 mg per mL (EMLc)

EML status history

First added in 2009 ([TRS 958](#))

Removed in 2021 ([TRS 1035](#))

Sex

All

Age

Newborn (< 1 month)

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Dinoprostone \(prostaglandin E2\)](#)

DrugBank

[Prostaglandin e2 \(Dinoprostone\)](#)

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended to retain the square box for prostaglandin E, but assign it to prostaglandin E1, and specify prostaglandin E2 as an alternative on the EMLc for this indication.